PUMA
Istituto di Fisiologia Clinica     
Andreassi M. G., Botto N., Laghi-Pasini F., Manfredi S., Ghelarducci B., Farneti P. A., Solinas M., Biagini A., Picano E. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. In: International Journal of Cardiology, vol. 101 (02) pp. 191 - 195. elsevier, 2005.
 
 
Abstract
(English)
Background: C34T variant of adenosine monophosphate deaminase 1 (AMPD1) gene has been associated with a prolonged survival in heart failure and coronary artery disease, hypothetically linked to an enhanced production of adenosine. Design: Since adenosine administration is a promising approach for the prevention of the ischemia-reperfusion in myocardial revascularization, the aim of this study was to investigate whether the AMPD1 (=) allele is associated with a favorable prognosis after coronary revascularization. In addition, we assessed the association between AMPD1 polymorphism and plasma adenosine levels. Methods: We investigated a total of 161 patients receiving coronary revascularization (70 percutaneous transluminal coronary angioplasty and 91 coronary artery bypass graft). They were investigated for a composite endpoint including recurrent angina, non-fatal MI, target vessel revascularization, heart failure and cardiac death. Plasma adenosine was also measured by high-performance liquid chromatography methods on a subset of 25 patients. Results: During the follow-up period (7.0F0.3 months), the overall combined endpoint accounted for 17 events (10 cardiacrelated deaths, 6 revascularization procedures and 1 congestive heart failure). The composite endpoint was 9.8% for AMPD1 (=) allele carriers vs. 11.5% for non-carriers (log-rank statistic, p = n.s.). In the logistic analysis only low ( V 40%) ejection fraction was an independent predictor of adverse events ( p = 0.01, OR= 3.8, 95% CI 1.3-11.4). Plasma adenosine levels were similar for AMPD1 (=) allele patients (n = 7) as compared for AMPD1 (+) allele (n = 18) subjects (290.5F31.0 vs. 303.3F28.5 nM, p = n.s.). Conclusions: Our results indicate that AMPD1 (=) allele is not associated with a more favorable outcome after coronary revascularization. Alternative cardioprotective pathways of the AMPD1 gene-involving an enhanced chronic long-term production of adenosine-might be responsible for survival.
URL: http://scienceserver.cilea.it/cgi-bin/sciserv.pl?collection=journals&journal=01675273&issue=v101i0002&article=191_apacoipumr&form=pdf&file=file.pdf
Subject Coronary artery disease
AMPD1 gene
PTCA
CABG
Clinical outcomes


Icona documento 1) Download Document PDF


Icona documento Open access Icona documento Restricted Icona documento Private

 


Per ulteriori informazioni, contattare: Librarian http://puma.isti.cnr.it

Valid HTML 4.0 Transitional